Potential drug target for tumors: CDCP1
The process of tumor cell infiltration, adhesion and migration is an important research direction in...
Feb 21, 2023
Cell and antibody therapies targeting HLA-G
On December 19, 2022, the FDA approved the Phase I/IIa clinical trial application of IVS-3001,...
Feb 14, 2023
A next-generation immunotherapy target TNFR2
The tumor necrosis factor (TNF) superfamily has important physiological significance in immune surveillance, tumor regression,...
Feb 10, 2023
New Products February 2023
Alkaline Phosphatase Alkaline Phosphatase (ALP) likely represents the most frequently assayed enzyme in all of...
Feb 07, 2023
TIDES Asia 2023
March 7-9th 2023: Meet us at TIDES Asia in Kyoto, Japan KACTUS will be at...
Jan 31, 2023
GARP-TGF-β1 Monoclonal Antibody Clinical Trial Approved by FDA
On January 4, 2023, Shanghai Jiyu Pharmaceutical announced that the IND application for its Class...
Jan 23, 2023
Focus on hematoma target FLT3
About FLT3 Fms-like tyrosine kinase 3 (FLT3) is also known as CD135 (Cluster of differentiation...
Jan 09, 2023